Skip to main content
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
Published Web Location
http://europepmc.org/articles/PMC3408577?pdf=renderNo data is associated with this publication.
Abstract
Human non-small cell lung cancers (NSCLCs) with activating mutations in EGFR frequently respond to treatment with EGFR-targeted tyrosine kinase inhibitors (TKIs), such as erlotinib, but responses are not durable, as tumors acquire resistance. Secondary mut
Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.